These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2476243)
1. Identification of a DTH-inducing T-cell epitope on the E2 membrane protein of Semliki Forest virus. Snijders A; Benaissa-Trouw BJ; Oosting JD; Snippe H; Kraaijeveld CA Cell Immunol; 1989 Oct; 123(1):23-35. PubMed ID: 2476243 [TBL] [Abstract][Full Text] [Related]
2. A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production. Snijders A; Benaissa-Trouw BJ; Visser-Vernooy HJ; Fernandez I; Snippe H; Kraaijeveld CA Immunology; 1992 Nov; 77(3):322-9. PubMed ID: 1282493 [TBL] [Abstract][Full Text] [Related]
3. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus. Fernández IM; Snijders A; Benaissa-Trouw BJ; Harmsen M; Snippe H; Kraaijeveld CA J Virol; 1993 Oct; 67(10):5843-8. PubMed ID: 7690411 [TBL] [Abstract][Full Text] [Related]
4. Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines. Fernández IM; Harmsen M; Benaissa-Trouw BJ; Stuij I; Puyk W; Meloen RH; Snippe H; Kraaijeveld CA Vaccine; 1998 Oct; 16(16):1531-6. PubMed ID: 9711800 [TBL] [Abstract][Full Text] [Related]
5. Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge. Grosfeld H; Velan B; Leitner M; Cohen S; Lustig S; Lachmi BE; Shafferman A J Virol; 1989 Aug; 63(8):3416-22. PubMed ID: 2473217 [TBL] [Abstract][Full Text] [Related]
6. Delineation of protective epitopes on the E2-envelope glycoprotein of Semliki Forest virus. Grosfeld H; Velan B; Leitner M; Lustig S; Lachi BE; Cohen S; Shafferman A Vaccine; 1991 Jun; 9(6):451-6. PubMed ID: 1716035 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant effects of dimethyl dioctadecyl ammonium bromide, complete Freund's adjuvant and aluminium hydroxide on neutralizing antibody, antibody-isotype and delayed-type hypersensitivity responses to Semliki Forest virus in mice. Katz D; Lehrer S; Galan O; Lachmi BE; Cohen S FEMS Microbiol Immunol; 1991 Nov; 3(6):305-20. PubMed ID: 1812932 [TBL] [Abstract][Full Text] [Related]
8. Delayed type hypersensitivity against semliki forest virus in mice: local transfer of delayed type hypersensitivity with thioglycollate-induced peritoneal exudate cells. Kraaijeveld CA; Benaissa-Trouw B; Harmsen M; Snippe H Int Arch Allergy Appl Immunol; 1984; 73(4):342-6. PubMed ID: 6698625 [TBL] [Abstract][Full Text] [Related]
9. A vaccine against Semliki Forest virus consisting of a monoclonal anti-idiotypic antibody cross-linked to a protein which contains virus-specific T-helper cell epitopes. Kraaijeveld CA; Oosterlaken TA; Snijders A; Benaissa-Trouw BJ; Ekstijn GL; Snippe H Antiviral Res; 1992 Oct; 19(4):275-84. PubMed ID: 1281391 [TBL] [Abstract][Full Text] [Related]
10. Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine. Snijders A; Benaissa-Trouw BJ; Oosterlaken TA; Puijk WC; Posthumus WP; Meloen RH; Boere WA; Oosting JD; Kraaijeveld CA; Snippe H J Gen Virol; 1991 Mar; 72 ( Pt 3)():557-65. PubMed ID: 1706409 [TBL] [Abstract][Full Text] [Related]
11. Dimethyl dioctadecyl ammoniumbromide as an adjuvant for delayed type hypersensitivity and cellular immunity against Semliki Forest virus in mice. Kraaijeveld CA; Snippe H; Harmsen M; Khader Boutahar-Trouw B Arch Virol; 1980; 65(3-4):211-7. PubMed ID: 7416968 [TBL] [Abstract][Full Text] [Related]
12. A shared idiotope among antibodies against Semliki Forest virus. Fernández IM; Ovaa W; Harmsen M; Benaissa-Trouw BJ; Bos NA; Kraaijeveld CA; Snippe H Viral Immunol; 1994; 7(2):71-80. PubMed ID: 7531444 [TBL] [Abstract][Full Text] [Related]
13. Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimaeric peptide consisting of a T-helper cell epitope of Semliki Forest virus and a B-cell epitope of HIV. Fernández IM; Golding H; Benaissa-Trouw BJ; de Vos NM; Harmsen M; Nottet HS; Golding B; Puijk WC; Meloen RH; Snippe H; Kraaijeveld CA Vaccine; 1998 Dec; 16(20):1936-40. PubMed ID: 9796047 [TBL] [Abstract][Full Text] [Related]
14. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Zhou X; Berglund P; Zhao H; Liljeström P; Jondal M Proc Natl Acad Sci U S A; 1995 Mar; 92(7):3009-13. PubMed ID: 7708765 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and vaccine efficacy of synthetic peptides containing Semliki Forest virus B and T cell epitopes. Snijders A; Benaissa-Trouw BJ; Snippe H; Kraaijeveld CA J Gen Virol; 1992 Sep; 73 ( Pt 9)():2267-72. PubMed ID: 1383405 [TBL] [Abstract][Full Text] [Related]
16. Cell-mediated immune responses to vaccine peptides derived from the circumsporozoite protein of Plasmodium falciparum. Russo DM; Sundy JS; Young JF; Maguire HC; Weidanz WP J Immunol; 1989 Jul; 143(2):655-9. PubMed ID: 2472448 [TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide and dimethyl dioctadecyl ammonium bromide immunopotentiate the delayed-type hypersensitivity response to inactivated enveloped viruses. Smith RH; Ziola B Immunology; 1986 Jun; 58(2):245-50. PubMed ID: 2423444 [TBL] [Abstract][Full Text] [Related]
18. Differential T cell response induced by certain recombinant oligopeptides of herpes simplex virus glycoprotein B in mice. Tizard ML; Chan WL J Gen Virol; 1997 Jul; 78 ( Pt 7)():1625-32. PubMed ID: 9225039 [TBL] [Abstract][Full Text] [Related]
19. Potentiation of the cellular immune response by adjuvants: a limited role for adjuvant induced interferon. Kraaijeveld CA; Kamphuis W; Benaissa-Trouw BJ; van Haarlem H; Harmsen M; Snippe H Int Arch Allergy Appl Immunol; 1986; 81(2):148-55. PubMed ID: 2428755 [TBL] [Abstract][Full Text] [Related]
20. Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities. Boere WA; Harmsen T; Vinjé J; Benaissa-Trouw BJ; Kraaijeveld CA; Snippe H J Virol; 1984 Nov; 52(2):575-82. PubMed ID: 6208379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]